Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2017 Jan 31;8(5):8717-8725.
doi: 10.18632/oncotarget.14427.

Influence of EGFR Mutational Status on Metastatic Behavior in Non Squamous Non Small Cell Lung Cancer

Affiliations
Free PMC article
Comparative Study

Influence of EGFR Mutational Status on Metastatic Behavior in Non Squamous Non Small Cell Lung Cancer

Alessandro Russo et al. Oncotarget. .
Free PMC article

Abstract

Epidermal Growth Factor Receptor (EGFR) mutated Non Small Cell Lung Cancers (NSCLCs) are a molecularly subgroup of patients with peculiar clinic-pathological characteristics. Previous studies have suggested a possible interaction between oncogene status and metastatic behavior in non squamous NSCLCs with conflicting results. The aim of this study was to compare the different metastatic patterns, at baseline and during the course of the disease, in a cohort of 137 Caucasian patients with non-squamous NSCLC according to the EGFR mutational status and survival differences according to the different metastatic behavior. We observed unique metastatic distributions between EGFR-mutated and EGFR wild type non-squamous NSCLCs. These data support the hypothesis that tumor bio-molecular characteristics and genotype may influence the metastatic process in NSCLC and might help the development of enrichment strategies for tumor genotyping in these tumors, especially in the presence of limited tissue availability.

Keywords: EGFR WT; EGFR mutations; NSCLC; brain metastases; metastatic spread.

Conflict of interest statement

CONFLICTS OF INTEREST

no potential conflicts of interest declared.

Figures

Figure 1
Figure 1. Metastatic pattern at baseline according to the EGFR mutational status
Figure 2
Figure 2. Median OS according to the EGFR mutational status in the overall population
Figure 3
Figure 3. Median OS in patients with Brain Metastases (BMs) according to the EGFR mutational status

Similar articles

See all similar articles

Cited by 5 articles

References

    1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108. - PubMed
    1. Russo A, Franchina T, Ricciardi GR, Picone A, Ferraro G, Zanghì M, Toscano G, Giordano A, Adamo V. A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives. Oncotarget. 2015;6:26814–25. doi: 10.18632/oncotarget.4254. - DOI - PMC - PubMed
    1. Oxnard GR, Binder A, Jänne PA. New targetable oncogenes in non-small-cell lung cancer. J Clin Oncol. 2013;31:1097–104. - PMC - PubMed
    1. Cancer Genome Atlas Research. Network. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014;511:543–50. - PMC - PubMed
    1. Gerber DE, Gandhi L, Costa DB. Management and future directions in non-small cell lung cancer with known activating mutations. Am Soc Clin Oncol Educ Book. 2014. pp. e353–65. - PubMed

Publication types

MeSH terms

Feedback